WASHINGTON — The Food and Drug Administration said on Monday it is revising the labeling of all extended-release stimulants used to treat attention-deficit hyperactivity disorder to include warnings ...

The FDA has accepted Otsuka’s New Drug Application for centanafadine, a first-in-class norepinephrine, dopamine and serotonin reuptake inhibitor (NDSRI) for the treatment of attention-deficit ...

The U.S. Food and Drug Administration (FDA) has announced a significant update to the labeling of all extended-release medications used to treat Attention-Deficit ...

The FDA now requires updated labeling for all extended-release stimulant medications used to treat attention deficit hyperactivity disorder, warning of increased risk of weight loss and other side ...

Extended-release stimulants are currently not approved for children younger than 6 years, but health care professionals do prescribe them "off label" to treat ADHD. Clinical trials have shown that ...

KANSAS CITY, Kan., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (CING) (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform ...

Kenvue, the American company that makes Tylenol, says the U.S. Food and Drug Administration should not make proposed changes to the product’s safety label to reflect research about a possible ...

But Vyvanse has already been on the market since 2007 as a daily treatment for attention deficit hyperactivity disorder (ADHD) in children and adults. So how does this drug act on two seemingly ...